Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?

Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates such as hormones, nutrients, and metabolites as well as of clinically important drugs. Several cancer therapeutics, ranging from chemotherapeuti...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancers Ročník 12; číslo 8; s. 2263
Hlavní autori: Brecht, Karin, Schäfer, Anima Magdalena, Meyer zu Schwabedissen, Henriette E.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Basel MDPI AG 12.08.2020
MDPI
Predmet:
ABC transporters
Cancer
Cancer therapies
Care and treatment
Carnitine
Cell division
Chemotherapy
DNA topoisomerase inhibitors
Drug metabolism
Drug therapy
Drugs
Etiology
Genes
Hormones
Kinases
Liver cancer
Metabolism
Metabolites
Nutrients
Observations
Organic anion transporting polypeptide
Pharmaceuticals
Pharmacokinetics
Polypeptides
Protein-tyrosine kinase
Proteins
Review
Studies
Thrombocytopenia
Toxicity
Tumor cells
Tumors
Switzerland
ISSN:2072-6694, 2072-6694
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates such as hormones, nutrients, and metabolites as well as of clinically important drugs. Several cancer therapeutics, ranging from chemotherapeutics such as topoisomerase inhibitors, DNA-intercalating drugs, and microtubule binders to targeted therapeutics such as tyrosine kinase inhibitors are substrates of solute carrier (SLC) transporters. Given that SLC transporters are expressed both in organs pivotal to drug absorption, distribution, metabolism, and elimination and in tumors, these transporters constitute determinants of cellular drug accumulation influencing intracellular drug concentration required for efficacy of the cancer treatment in tumor cells. In this review, we explore the current understanding of members of three SLC families, namely SLC21 (organic anion transporting polypeptides, OATPs), SLC22A (organic cation transporters, OCTs; organic cation/carnitine transporters, OCTNs; and organic anion transporters OATs), and SLC15A (peptide transporters, PEPTs) in the etiology of cancer, in transport of chemotherapeutic drugs, and their influence on efficacy or toxicity of pharmacotherapy. We further explore the idea to exploit the function of SLC transporters to enhance cancer cell accumulation of chemotherapeutics, which would be expected to reduce toxic side effects in healthy tissue and to improve efficacy.
AbstractList Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates such as hormones, nutrients, and metabolites as well as of clinically important drugs. Several cancer therapeutics, ranging from chemotherapeutics such as topoisomerase inhibitors, DNA-intercalating drugs, and microtubule binders to targeted therapeutics such as tyrosine kinase inhibitors are substrates of solute carrier (SLC) transporters. Given that SLC transporters are expressed both in organs pivotal to drug absorption, distribution, metabolism, and elimination and in tumors, these transporters constitute determinants of cellular drug accumulation influencing intracellular drug concentration required for efficacy of the cancer treatment in tumor cells. In this review, we explore the current understanding of members of three SLC families, namely SLC21 (organic anion transporting polypeptides, OATPs), SLC22A (organic cation transporters, OCTs; organic cation/carnitine transporters, OCTNs; and organic anion transporters OATs), and SLC15A (peptide transporters, PEPTs) in the etiology of cancer, in transport of chemotherapeutic drugs, and their influence on efficacy or toxicity of pharmacotherapy. We further explore the idea to exploit the function of SLC transporters to enhance cancer cell accumulation of chemotherapeutics, which would be expected to reduce toxic side effects in healthy tissue and to improve efficacy.
Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates such as hormones, nutrients, and metabolites as well as of clinically important drugs. Several cancer therapeutics, ranging from chemotherapeutics such as topoisomerase inhibitors, DNA-intercalating drugs, and microtubule binders to targeted therapeutics such as tyrosine kinase inhibitors are substrates of solute carrier (SLC) transporters. Given that SLC transporters are expressed both in organs pivotal to drug absorption, distribution, metabolism, and elimination and in tumors, these transporters constitute determinants of cellular drug accumulation influencing intracellular drug concentration required for efficacy of the cancer treatment in tumor cells. In this review, we explore the current understanding of members of three SLC families, namely SLC21 (organic anion transporting polypeptides, OATPs), SLC22A (organic cation transporters, OCTs; organic cation/carnitine transporters, OCTNs; and organic anion transporters OATs), and SLC15A (peptide transporters, PEPTs) in the etiology of cancer, in transport of chemotherapeutic drugs, and their influence on efficacy or toxicity of pharmacotherapy. We further explore the idea to exploit the function of SLC transporters to enhance cancer cell accumulation of chemotherapeutics, which would be expected to reduce toxic side effects in healthy tissue and to improve efficacy.Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates such as hormones, nutrients, and metabolites as well as of clinically important drugs. Several cancer therapeutics, ranging from chemotherapeutics such as topoisomerase inhibitors, DNA-intercalating drugs, and microtubule binders to targeted therapeutics such as tyrosine kinase inhibitors are substrates of solute carrier (SLC) transporters. Given that SLC transporters are expressed both in organs pivotal to drug absorption, distribution, metabolism, and elimination and in tumors, these transporters constitute determinants of cellular drug accumulation influencing intracellular drug concentration required for efficacy of the cancer treatment in tumor cells. In this review, we explore the current understanding of members of three SLC families, namely SLC21 (organic anion transporting polypeptides, OATPs), SLC22A (organic cation transporters, OCTs; organic cation/carnitine transporters, OCTNs; and organic anion transporters OATs), and SLC15A (peptide transporters, PEPTs) in the etiology of cancer, in transport of chemotherapeutic drugs, and their influence on efficacy or toxicity of pharmacotherapy. We further explore the idea to exploit the function of SLC transporters to enhance cancer cell accumulation of chemotherapeutics, which would be expected to reduce toxic side effects in healthy tissue and to improve efficacy.
Audience Academic
Author Brecht, Karin
Schäfer, Anima Magdalena
Meyer zu Schwabedissen, Henriette E.
AuthorAffiliation Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland; anima.schaefer@unibas.ch (A.M.S.); h.meyerzuschwabedissen@unibas.ch (H.E.M.z.S.)
AuthorAffiliation_xml – name: Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland; anima.schaefer@unibas.ch (A.M.S.); h.meyerzuschwabedissen@unibas.ch (H.E.M.z.S.)
Author_xml – sequence: 1
  givenname: Karin
  surname: Brecht
  fullname: Brecht, Karin
– sequence: 2
  givenname: Anima Magdalena
  surname: Schäfer
  fullname: Schäfer, Anima Magdalena
– sequence: 3
  givenname: Henriette E.
  surname: Meyer zu Schwabedissen
  fullname: Meyer zu Schwabedissen, Henriette E.
BookMark eNp1Uk1v1DAUtFARLUvPXC1x4dCljh07zgUUrVpAWgQSy9l66zhdt4kdbAdpb9z4A_xCfgkOW_GxEr689-SZ8Yz8HqMT551B6GlBXjBWk0sNTpsQC0okpYI9QGeUVHQpRF2e_NWfovMYb0k-jBWVqB6hU0YlERURZ-jbpzHBncGbAC6OPqQsiH2H087gj-sVLS5-FdpcYHDt3Be8wdcw2N6aiK3DjUv24ARvdibAuP_x9fs73049JH8QW5m-z2PAVy6FPfYBf9hBGED7O-tMpsdXT9DDDvpozu_rAm2urzarN8v1-9dvV816qcuapiXnLduyLe8q2EpDjCQEWMuo4YxUps7xKJVaAG2FJG0eoSwLLaWpy1Ywzhbo5UF2nLaDabXJhqBXY7ADhL3yYNW_N87u1I3_oqpSlKwiWeD5vUDwnycTkxps1DkfOOOnqGjJeCEFy_-xQM-OoLd-Ci6nm1Ell5wJ-gd1A71R1nU-v6tnUdUIVtei5mWRUZcHlA4-xmC635YLouZlUEfLkBn8iKFtgmT9nMv2_-X9BDIKuew
CitedBy_id crossref_primary_10_3390_pharmaceutics13060834
crossref_primary_10_1016_j_jhazmat_2022_130409
crossref_primary_10_1080_10286020_2025_2482054
crossref_primary_10_1080_14740338_2024_2376690
crossref_primary_10_3390_cancers13174343
crossref_primary_10_3390_ijms222312926
crossref_primary_10_3389_fonc_2020_598801
crossref_primary_10_1080_17425255_2022_2132932
crossref_primary_10_1186_s12964_023_01302_1
crossref_primary_10_1186_s12957_022_02571_9
crossref_primary_10_1016_j_bcp_2022_115251
crossref_primary_10_3389_fnins_2024_1442915
crossref_primary_10_3390_cancers15072119
crossref_primary_10_1007_s10620_025_09214_5
crossref_primary_10_1007_s00232_025_00348_1
crossref_primary_10_1016_j_pharmthera_2024_108728
crossref_primary_10_1080_17425255_2022_2113380
crossref_primary_10_1016_j_ejps_2023_106686
crossref_primary_10_3389_fphar_2023_1191262
crossref_primary_10_3389_fmolb_2022_893846
Cites_doi 10.1038/clpt.2011.42
10.1080/17512433.2019.1581605
10.1007/s10549-014-2913-y
10.1021/acs.molpharmaceut.8b00631
10.1053/gast.2001.21176
10.1124/jpet.106.110346
10.2967/jnumed.107.048231
10.1038/183263a0
10.1038/bjc.2015.5
10.1586/1744666X.2014.962996
10.1023/A:1011904027137
10.1002/ibd.21814
10.1038/s41568-018-0005-8
10.1124/dmd.112.048181
10.1177/1758834016642370
10.1158/1535-7163.MCT-09-1084
10.3390/molecules25010014
10.1074/jbc.M103792200
10.2174/1389200013338748
10.1093/ndt/gfp456
10.1186/1471-230X-12-78
10.1111/j.1476-5381.2011.01724.x
10.18632/oncotarget.15029
10.1158/1078-0432.CCR-07-4118
10.1186/s13046-017-0523-3
10.1016/j.pdpdt.2013.02.001
10.1002/1097-0215(20001015)88:2<274::AID-IJC20>3.0.CO;2-5
10.1146/annurev-pharmtox-010510-100556
10.1007/s00210-007-0219-x
10.1172/JCI1909
10.1007/s10549-011-1925-0
10.1016/j.phrs.2012.10.015
10.1002/jbt.22513
10.2174/1389200216666150812142715
10.1111/cas.12602
10.1124/dmd.114.059097
10.1211/0022357055966
10.1128/MCB.23.9.3247-3252.2003
10.1021/bc9901088
10.1158/1078-0432.CCR-10-1239
10.1007/s10545-010-9061-2
10.1097/FJC.0b013e3181abc288
10.1021/mp3005353
10.4161/cbt.7.9.6282
10.1111/j.1476-5381.2009.00430.x
10.1124/mol.116.105544
10.1182/blood-2003-12-4276
10.1158/0008-5472.CAN-06-0769
10.1016/j.fct.2012.03.077
10.1002/cpt.1301
10.1111/j.1365-2125.2008.03303.x
10.3390/children5110145
10.1172/JCI42168
10.1074/jbc.274.24.17159
10.1016/j.ejps.2018.05.006
10.1124/jpet.111.181297
10.1002/lsm.22613
10.1016/j.drup.2010.12.002
10.1124/dmd.117.079384
10.1073/pnas.48.12.2094
10.1016/j.ejps.2014.06.019
10.1002/cpt.888
10.1016/j.bcp.2017.12.012
10.1016/1011-1344(92)85108-7
10.1016/j.bcp.2006.06.007
10.1021/acs.molpharmaceut.8b00588
10.3322/caac.21492
10.1016/j.ctrv.2018.06.013
10.1158/1078-0432.CCR-12-3306
10.1097/FPC.0b013e328342f5b1
10.1016/0006-2952(94)90421-9
10.1016/j.ejca.2018.01.065
10.1016/j.taap.2020.115039
10.4161/cbt.11.6.14533
10.1002/cpt.1588
10.1124/dmd.105.004283
10.1158/1078-0432.CCR-18-2380
10.1124/jpet.108.143339
10.1124/dmd.108.023168
10.1124/mol.118.114314
10.2217/14622416.8.6.567
10.1016/j.xphs.2017.04.004
10.1161/CIRCRESAHA.109.203596
10.1111/j.1476-5381.2009.00569.x
10.1186/s40169-014-0037-y
10.1124/pr.110.002857
10.1111/cts.12476
10.1016/j.phrs.2014.11.002
10.1111/bcp.13207
10.1074/jbc.273.32.20378
10.1136/bmj.1.6120.1097
10.1074/jbc.270.43.25672
10.2133/dmpk.DMPK-12-RV-099
10.1158/1940-6207.CAPR-20-0014
10.1007/s004240000339
10.1016/j.peptides.2012.01.007
10.1124/dmd.115.066712
10.1124/jpet.112.192344
10.1056/NEJM195809042591003
10.18632/oncotarget.20637
10.1371/journal.pone.0064069
10.1007/s00595-016-1328-2
10.1158/1078-0432.CCR-12-2080
10.1016/j.jphs.2019.01.012
10.4161/cbt.11.9.15176
10.1002/cpt.315
10.1016/j.mam.2012.12.009
10.1186/gm405
10.1182/blood-2007-06-093617
10.1002/ijc.31937
10.1002/cpt.1710
10.1007/s10549-010-1046-1
10.1124/jpet.106.104364
10.1002/jps.22752
10.1038/368563a0
10.3892/ijo.2017.4167
10.1038/clpt.2009.139
10.1158/1535-7163.MCT-18-0739
10.3892/ijo.2013.1840
10.2307/3273703
10.1158/0008-5472.CAN-16-2548
10.1016/S0014-5793(97)01441-5
10.1016/S1470-2045(04)01529-3
10.2133/dmpk.19.369
10.3390/genes10050364
10.1158/1535-7163.MCT-11-0980
10.1208/s12248-013-9515-1
10.1158/1078-0432.CCR-09-0048
10.1158/0008-5472.CAN-05-1070
10.1158/0008-5472.CAN-15-0280
10.1002/cncr.21227
10.1016/j.jcmgh.2016.01.006
10.1200/JCO.2015.62.5988
10.2217/pgs-2016-0063
10.1158/1535-7163.MCT-12-0926
10.1124/dmd.117.077289
10.1016/j.lungcan.2007.07.019
10.1371/journal.pone.0065200
10.1038/clpt.2011.102
10.1186/gm298
10.1093/jnci/95.8.605
10.1080/10717544.2017.1377316
10.1007/s00726-013-1648-0
10.2471/BLT.15.163998
10.1007/BF02174207
10.1007/s11095-013-1117-1
10.1007/s00228-018-2544-z
10.1016/j.bcp.2012.07.026
10.1158/0008-5472.CAN-05-1271
10.1124/pr.118.015578
10.1007/s00726-019-02739-w
10.18632/oncotarget.3758
10.1186/1471-2407-12-109
10.1161/CIRCULATIONAHA.105.586107
10.1038/clpt.2013.145
10.3324/haematol.2011.056457
10.1111/j.1365-2125.2011.04123.x
10.1158/1078-0432.CCR-13-1999
10.1021/mp300364k
10.1016/j.bcp.2007.03.004
10.1001/archsurg.1993.01420240081016
10.1007/s00280-006-0341-3
10.1111/cts.12480
10.1016/j.pharmthera.2018.12.009
10.1007/s00259-008-0745-x
10.1002/ijc.28970
10.1002/cpt.1373
10.1158/1078-0432.CCR-12-0761
10.1111/bph.14563
10.1186/s12957-017-1239-8
10.1177/106002809202600219
10.1021/mp8001655
10.1038/tpj.2016.83
10.1158/1055-9965.EPI-10-1023
10.1124/dmd.118.080440
10.1074/jbc.273.10.5582
10.1007/s40262-016-0439-7
10.1158/0008-5472.CAN-08-0265
10.1124/dmd.119.087619
10.1038/clpt.2008.95
10.18632/oncotarget.17117
10.1172/JCI59526
10.1007/s10549-015-3552-7
10.1016/0006-2952(93)90431-U
10.1006/bbrc.2000.2922
10.1016/0005-2736(95)80036-F
10.1038/s41422-020-0337-2
10.1200/JCO.2014.59.5256
10.1371/journal.pone.0148739
10.1111/cts.12458
10.1681/ASN.V134866
10.1124/mol.112.083618
10.1016/j.drup.2016.06.005
10.1186/s12885-017-3728-0
10.1158/1535-7163.MCT-14-0547
10.2217/fon.10.51
10.1186/s12885-016-2150-3
10.1053/gast.2001.24804
10.1021/acs.molpharmaceut.0c00159
10.1158/1535-7163.MCT-13-0541
10.3324/haematol.2012.066480
10.1038/leu.2015.170
10.1016/j.bbrc.2012.01.115
10.1016/j.canlet.2004.12.023
10.1002/bdd.2091
10.1007/s00424-003-1168-y
10.1124/dmd.119.090316
10.3390/molecules25030643
10.1159/000381313
10.1080/00498250600861751
10.1002/hep.26425
10.1038/sj.clpt.6100056
10.1158/1078-0432.CCR-07-4913
10.1158/1078-0432.CCR-16-2245
10.1016/0016-5085(95)90588-X
10.1016/0065-2571(94)90025-6
10.1016/j.etap.2017.08.008
10.1016/j.vph.2015.06.006
10.1248/bpb.33.1867
10.1124/mol.61.4.853
ContentType Journal Article
Copyright COPYRIGHT 2020 MDPI AG
2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2020 by the authors. 2020
Copyright_xml – notice: COPYRIGHT 2020 MDPI AG
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2020 by the authors. 2020
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers12082263
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Biological Science Collection
Research Library
Biological Science Database
Research Library (Corporate)
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC7464370
A639969541
10_3390_cancers12082263
GeographicLocations Switzerland
GeographicLocations_xml – name: Switzerland
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
RPM
TUS
3V.
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c492t-55d3b3b5f7ab8e0e800a3d32e5307e9176228c6a2d680d176a441c88e94d6353
IEDL.DBID BENPR
ISICitedReferencesCount 25
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000578905300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2072-6694
IngestDate Tue Nov 04 02:00:00 EST 2025
Wed Oct 01 14:10:24 EDT 2025
Fri Jul 25 12:00:48 EDT 2025
Tue Nov 11 10:24:29 EST 2025
Sat Nov 29 07:13:41 EST 2025
Tue Nov 18 21:31:40 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c492t-55d3b3b5f7ab8e0e800a3d32e5307e9176228c6a2d680d176a441c88e94d6353
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors have equally contributed to this work.
OpenAccessLink https://www.proquest.com/docview/2434585362?pq-origsite=%requestingapplication%
PMID 32806706
PQID 2434585362
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7464370
proquest_miscellaneous_2435186326
proquest_journals_2434585362
gale_infotracmisc_A639969541
crossref_primary_10_3390_cancers12082263
crossref_citationtrail_10_3390_cancers12082263
PublicationCentury 2000
PublicationDate 20200812
PublicationDateYYYYMMDD 2020-08-12
PublicationDate_xml – month: 8
  year: 2020
  text: 20200812
  day: 12
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2020
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Hagiya (ref_193) 2013; 10
Li (ref_151) 2012; 101
Zimmerman (ref_18) 2013; 19
Frey (ref_226) 2003; 23
ref_131
Tai (ref_195) 2013; 10
Hediger (ref_6) 2013; 34
Geier (ref_31) 2017; 8
Lozano (ref_33) 2019; 176
Cipriani (ref_109) 2014; 10
ref_132
Roth (ref_8) 2012; 165
Wang (ref_177) 2012; 134
Willighagen (ref_203) 1959; 183
Farag (ref_106) 2017; 56
Zhou (ref_48) 2013; 15
Irie (ref_219) 2001; 298
Arndt (ref_229) 2018; 68
Criado (ref_126) 2000; 11
Lee (ref_61) 2015; 14
Alex (ref_124) 2016; 8
Margolis (ref_36) 1954; 40
Kennedy (ref_217) 1992; 14
Tatsumi (ref_57) 2014; 7
Hu (ref_225) 2008; 5
Swift (ref_27) 2013; 41
Gschwind (ref_99) 2005; 33
Miyabe (ref_221) 2019; 139
Briz (ref_166) 2002; 61
Yonezawa (ref_150) 2006; 319
Burger (ref_153) 2010; 159
Hagenbuch (ref_88) 1995; 109
Huennekens (ref_97) 1994; 34
Hashimoto (ref_58) 2014; 145
Suzuki (ref_113) 2009; 67
Hamada (ref_69) 2008; 14
ref_159
Arakawa (ref_86) 2012; 84
Katsuda (ref_157) 2010; 33
Robertson (ref_3) 2016; 94
Grube (ref_168) 2006; 113
Hahn (ref_41) 2019; 18
Iusuf (ref_60) 2015; 136
Stranecky (ref_21) 2012; 122
Benard (ref_84) 2008; 35
Ferreira (ref_119) 2018; 120
Bleasby (ref_116) 2006; 36
ref_148
Oppermann (ref_194) 2019; 51
ref_82
Tamai (ref_89) 2000; 273
Bauer (ref_141) 2018; 104
Ferlay (ref_1) 2019; 144
Chen (ref_26) 2020; 107
Lee (ref_34) 2015; 6
Sprowl (ref_158) 2013; 94
Sankaranarayanan (ref_181) 2020; 21
Baker (ref_63) 2009; 85
Takano (ref_205) 1994; 47
Abe (ref_11) 2001; 120
Fujita (ref_39) 2016; 44
Pusztai (ref_128) 2005; 104
Ballestero (ref_77) 2006; 72
Hussner (ref_120) 2015; 72
Lal (ref_85) 2007; 8
Tirona (ref_79) 2008; 68
Obaidat (ref_13) 2012; 52
Liedauer (ref_76) 2009; 22
Badagnani (ref_98) 2006; 318
Imai (ref_72) 2013; 30
Fei (ref_188) 1994; 368
Bao (ref_95) 2020; 107
Liu (ref_189) 1995; 1235
Ichinose (ref_210) 2003; 95
Hu (ref_187) 2012; 11
White (ref_104) 2012; 97
Abete (ref_144) 2019; 12
Hsu (ref_52) 2017; 8
Tschirka (ref_174) 2018; 46
Bauer (ref_121) 2018; 15
Hagenbuch (ref_9) 2004; 447
Medwid (ref_140) 2019; 47
Rutenburg (ref_201) 1958; 259
Mrsny (ref_190) 1998; 15
Schulte (ref_66) 2019; 95
Lancaster (ref_186) 2010; 16
Wang (ref_199) 2014; 63
Robey (ref_5) 2018; 18
Haschke (ref_184) 2010; 25
Aherne (ref_111) 1978; 1
Tamai (ref_170) 1997; 419
Gao (ref_91) 2000; 294
Allison (ref_212) 2010; 6
Angelini (ref_46) 2013; 68
Bray (ref_2) 2018; 68
Durmus (ref_20) 2016; 27
Terada (ref_191) 2000; 440
ref_231
Viennois (ref_127) 2016; 2
Niemi (ref_16) 2011; 63
Narumi (ref_114) 2017; 38
Dachineni (ref_182) 2017; 51
Burger (ref_149) 2011; 14
Houten (ref_176) 2010; 33
Koepsell (ref_143) 2020; 72
Marada (ref_163) 2015; 91
Lautem (ref_147) 2013; 42
ref_224
Zhu (ref_208) 2012; 33
Drenberg (ref_51) 2016; 99
ref_220
Hubeny (ref_93) 2020; 17
Chen (ref_139) 2020; 48
Nies (ref_102) 2014; 20
Kobayashi (ref_162) 2005; 57
Ismair (ref_115) 2001; 120
Martini (ref_179) 2012; 18
Frenia (ref_112) 1992; 26
Yabuuchi (ref_173) 1999; 289
Bins (ref_25) 2016; 17
Thakkar (ref_71) 2013; 10
Billington (ref_94) 2019; 106
Wang (ref_123) 2016; 34
Nakanishi (ref_200) 2000; 88
Tashiro (ref_55) 2014; 4
Hu (ref_96) 2008; 14
Schaefer (ref_122) 2018; 15
Yokoo (ref_155) 2007; 74
Knutter (ref_35) 2008; 327
Abe (ref_10) 1999; 274
Jong (ref_175) 2011; 338
Goldberg (ref_228) 1962; 48
Tamai (ref_171) 1998; 273
Mostaghel (ref_40) 2017; 23
Malagnino (ref_12) 2018; 148
Herraez (ref_28) 2013; 58
Kishi (ref_214) 2016; 46
Warner (ref_4) 2020; 30
Knauer (ref_137) 2013; 83
Hitzerd (ref_204) 2014; 46
Kindla (ref_136) 2011; 11
Ateyya (ref_130) 2017; 55
McFeely (ref_138) 2019; 196
Gong (ref_107) 2013; 28
Jaruskova (ref_100) 2017; 36
Drozdzik (ref_117) 2019; 105
Hu (ref_161) 2017; 10
Gong (ref_198) 2017; 8
Sun (ref_74) 2014; 3
Nishino (ref_54) 2013; 1
More (ref_154) 2010; 9
Yu (ref_90) 2017; 106
Kim (ref_227) 2018; 74
Morrissey (ref_23) 2017; 10
Billington (ref_134) 2018; 46
Fink (ref_178) 2019; 25
Ganapathy (ref_192) 1995; 270
Schaeffeler (ref_32) 2011; 3
Kou (ref_125) 2017; 24
Teft (ref_38) 2015; 112
Miki (ref_78) 2006; 66
Gonzalez (ref_197) 1998; 58
Nies (ref_70) 2013; 5
Iusuf (ref_19) 2014; 13
Glaeser (ref_169) 2007; 81
Lee (ref_15) 2017; 83
Nieskens (ref_160) 2018; 46
Lancaster (ref_64) 2012; 18
Yamakawa (ref_45) 2011; 90
Callens (ref_50) 2015; 153
Brown (ref_211) 2004; 5
Ota (ref_209) 1992; 4
Bins (ref_24) 2017; 10
Gaspar (ref_230) 2015; 33
Zhou (ref_75) 2015; 95
Kenady (ref_83) 1993; 128
Harada (ref_216) 2018; 16
Wongthai (ref_222) 2015; 106
Vasilyeva (ref_22) 2015; 75
Furihata (ref_129) 2015; 16
Doring (ref_218) 1998; 101
Scornik (ref_202) 2001; 2
Kalliokoski (ref_17) 2009; 158
ref_172
ref_56
Lancaster (ref_165) 2013; 12
Nies (ref_145) 2008; 376
Banerjee (ref_81) 2012; 342
Nagai (ref_73) 2012; 418
Wagenaar (ref_59) 2013; 19
Choudhuri (ref_67) 2020; 399
Zhang (ref_152) 2006; 66
Knauer (ref_118) 2010; 106
Motohashi (ref_146) 2002; 13
Mancinelli (ref_185) 2007; 60
Drenberg (ref_53) 2017; 77
Wright (ref_87) 2011; 20
Wagenaar (ref_108) 2010; 120
Mitsuoka (ref_223) 2008; 49
Zou (ref_180) 2018; 93
Tirona (ref_14) 2001; 276
Han (ref_37) 2008; 59
Kloth (ref_49) 2018; 18
Schwarz (ref_68) 2011; 21
Watkins (ref_105) 2015; 29
Hu (ref_29) 2009; 15
Terada (ref_207) 1998; 273
Yokoo (ref_164) 2008; 36
Wlcek (ref_135) 2008; 7
Yagi (ref_213) 2017; 15
ref_30
Eechoute (ref_43) 2011; 89
White (ref_103) 2007; 110
Wlcek (ref_133) 2011; 11
Bronger (ref_92) 2005; 65
Justenhoven (ref_80) 2011; 125
Zhang (ref_42) 2012; 50
Thomas (ref_101) 2004; 104
Inoue (ref_196) 2005; 230
ref_47
ref_183
Lee (ref_62) 2017; 91
Hillemanns (ref_215) 2017; 49
Uwai (ref_110) 2004; 19
McBride (ref_167) 2009; 54
Angelini (ref_44) 2013; 98
Hori (ref_206) 1993; 45
Chew (ref_65) 2012; 73
ref_7
Johnston (ref_142) 2014; 42
Filipski (ref_156) 2009; 86
References_xml – volume: 89
  start-page: 816
  year: 2011
  ident: ref_43
  article-title: Environmental and genetic factors affecting transport of imatinib by oatp1a2
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2011.42
– volume: 289
  start-page: 768
  year: 1999
  ident: ref_173
  article-title: Novel membrane transporter octn1 mediates multispecific, bidirectional, and ph-dependent transport of organic cations
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 12
  start-page: 329
  year: 2019
  ident: ref_144
  article-title: Unraveling ‘the cancer genome atlas’ information on the role of slc transporters in anticancer drug uptake
  publication-title: Expert Rev. Clin. Pharmacol.
  doi: 10.1080/17512433.2019.1581605
– volume: 145
  start-page: 101
  year: 2014
  ident: ref_58
  article-title: Expression of organic anion-transporting polypeptide 1a2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-014-2913-y
– volume: 15
  start-page: 5501
  year: 2018
  ident: ref_122
  article-title: Establishment and validation of competitive counterflow as a method to detect substrates of the organic anion transporting polypeptide 2b1
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.8b00631
– volume: 120
  start-page: 525
  year: 2001
  ident: ref_115
  article-title: Organic anion-transporting polypeptide b (oatp-b) and its functional comparison with three other oatps of human liver
  publication-title: Gastroenterology
  doi: 10.1053/gast.2001.21176
– volume: 319
  start-page: 879
  year: 2006
  ident: ref_150
  article-title: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (slc22a1-3 and multidrug and toxin extrusion family)
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.106.110346
– volume: 49
  start-page: 615
  year: 2008
  ident: ref_223
  article-title: Cancer detection using a pet tracer, 11c-glycylsarcosine, targeted to h+/peptide transporter
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.107.048231
– volume: 183
  start-page: 263
  year: 1959
  ident: ref_203
  article-title: Aminopeptidase activity in cancer cells
  publication-title: Nature
  doi: 10.1038/183263a0
– volume: 112
  start-page: 857
  year: 2015
  ident: ref_38
  article-title: Oatp1b1 and tumour oatp1b3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.5
– volume: 10
  start-page: 1519
  year: 2014
  ident: ref_109
  article-title: Methotrexate: An old new drug in autoimmune disease
  publication-title: Expert Rev. Clin. Immunol.
  doi: 10.1586/1744666X.2014.962996
– volume: 15
  start-page: 816
  year: 1998
  ident: ref_190
  article-title: Oligopeptide transporters as putative therapeutic targets for cancer cells
  publication-title: Pharm. Res.
  doi: 10.1023/A:1011904027137
– volume: 18
  start-page: 439
  year: 2012
  ident: ref_179
  article-title: Association of the octn1/1672t variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients
  publication-title: Inflamm. Bowel Dis.
  doi: 10.1002/ibd.21814
– volume: 18
  start-page: 452
  year: 2018
  ident: ref_5
  article-title: Revisiting the role of abc transporters in multidrug-resistant cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-018-0005-8
– volume: 41
  start-page: 1179
  year: 2013
  ident: ref_27
  article-title: Sorafenib hepatobiliary disposition: Mechanisms of hepatic uptake and disposition of generated metabolites
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.112.048181
– volume: 8
  start-page: 267
  year: 2016
  ident: ref_124
  article-title: Cyp17 inhibitors in prostate cancer: Latest evidence and clinical potential
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758834016642370
– volume: 9
  start-page: 1058
  year: 2010
  ident: ref_154
  article-title: Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-09-1084
– ident: ref_172
  doi: 10.3390/molecules25010014
– volume: 276
  start-page: 35669
  year: 2001
  ident: ref_14
  article-title: Polymorphisms in oatp-c: Identification of multiple allelic variants associated with altered transport activity among european- and african-americans
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M103792200
– volume: 2
  start-page: 67
  year: 2001
  ident: ref_202
  article-title: Bestatin as an experimental tool in mammals
  publication-title: Curr. Drug Metab.
  doi: 10.2174/1389200013338748
– volume: 25
  start-page: 426
  year: 2010
  ident: ref_184
  article-title: Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfp456
– ident: ref_132
  doi: 10.1186/1471-230X-12-78
– volume: 165
  start-page: 1260
  year: 2012
  ident: ref_8
  article-title: Oatps, oats and octs: The organic anion and cation transporters of the slco and slc22a gene superfamilies
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2011.01724.x
– volume: 8
  start-page: 15846
  year: 2017
  ident: ref_31
  article-title: The lack of the organic cation transporter oct1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15029
– volume: 14
  start-page: 3312
  year: 2008
  ident: ref_69
  article-title: Effect of slco1b3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-4118
– volume: 36
  start-page: 55
  year: 2017
  ident: ref_100
  article-title: Genotypes of slc22a4 and slc22a5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-017-0523-3
– volume: 10
  start-page: 288
  year: 2013
  ident: ref_193
  article-title: Expression levels of pept1 and abcg2 play key roles in 5-aminolevulinic acid (ala)-induced tumor-specific protoporphyrin ix (ppix) accumulation in bladder cancer
  publication-title: Photodiagn. Photodyn. Ther.
  doi: 10.1016/j.pdpdt.2013.02.001
– volume: 88
  start-page: 274
  year: 2000
  ident: ref_200
  article-title: Cancer cell-targeted drug delivery utilizing oligopeptide transport activity
  publication-title: Int. J. Cancer
  doi: 10.1002/1097-0215(20001015)88:2<274::AID-IJC20>3.0.CO;2-5
– volume: 52
  start-page: 135
  year: 2012
  ident: ref_13
  article-title: The expression and function of organic anion transporting polypeptides in normal tissues and in cancer
  publication-title: Annu. Rev. Pharmacol. Toxicol.
  doi: 10.1146/annurev-pharmtox-010510-100556
– volume: 298
  start-page: 711
  year: 2001
  ident: ref_219
  article-title: Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in caco-2 cells
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 376
  start-page: 449
  year: 2008
  ident: ref_145
  article-title: Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (oct1, slc22a1) and the efflux pump mdr1 p-glycoprotein (abcb1)
  publication-title: Naunyn Schmiedebergs Arch. Pharmacol.
  doi: 10.1007/s00210-007-0219-x
– volume: 101
  start-page: 2761
  year: 1998
  ident: ref_218
  article-title: Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI1909
– volume: 134
  start-page: 101
  year: 2012
  ident: ref_177
  article-title: Slc22a5/octn2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ere)
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-011-1925-0
– volume: 68
  start-page: 1
  year: 2013
  ident: ref_46
  article-title: Polymorphisms in octn1 and octn2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2012.10.015
– ident: ref_47
  doi: 10.1002/jbt.22513
– volume: 16
  start-page: 474
  year: 2015
  ident: ref_129
  article-title: Cancer-type organic anion transporting polypeptide 1b3: Current knowledge of the gene structure, expression profile, functional implications and future perspectives
  publication-title: Curr. Drug Metab.
  doi: 10.2174/1389200216666150812142715
– volume: 106
  start-page: 279
  year: 2015
  ident: ref_222
  article-title: Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by atb0,+, lat1 and lat2
  publication-title: Cancer Sci.
  doi: 10.1111/cas.12602
– volume: 21
  start-page: 20
  year: 2020
  ident: ref_181
  article-title: Aspirin metabolites 2,3dhba and 2,5dhba inhibit cancer cell growth: Implications in colorectal cancer prevention
  publication-title: Mol. Med. Rep.
– volume: 42
  start-page: 1851
  year: 2014
  ident: ref_142
  article-title: Selective inhibition of human solute carrier transporters by multikinase inhibitors
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.114.059097
– volume: 57
  start-page: 573
  year: 2005
  ident: ref_162
  article-title: Transport mechanism and substrate specificity of human organic anion transporter 2 (hoat2 [slc22a7])
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1211/0022357055966
– volume: 23
  start-page: 3247
  year: 2003
  ident: ref_226
  article-title: Targeted disruption of the peptide transporter pept2 gene in mice defines its physiological role in the kidney
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.23.9.3247-3252.2003
– volume: 11
  start-page: 167
  year: 2000
  ident: ref_126
  article-title: Structural characterization, kinetic studies, and in vitro biological activity of new cis-diamminebis-cholylglycinate(o,o’) pt(ii) and cis-diamminebis-ursodeoxycholate(o,o’) pt(ii) complexes
  publication-title: Bioconjug. Chem.
  doi: 10.1021/bc9901088
– volume: 16
  start-page: 4789
  year: 2010
  ident: ref_186
  article-title: Cisplatin-induced downregulation of octn2 affects carnitine wasting
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-1239
– volume: 33
  start-page: 469
  year: 2010
  ident: ref_176
  article-title: A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation
  publication-title: J. Inherit. Metab. Dis.
  doi: 10.1007/s10545-010-9061-2
– volume: 54
  start-page: 63
  year: 2009
  ident: ref_167
  article-title: The organic cation transporter, octn1, expressed in the human heart, potentiates antagonism of the herg potassium channel
  publication-title: J. Cardiovasc. Pharmacol.
  doi: 10.1097/FJC.0b013e3181abc288
– volume: 10
  start-page: 406
  year: 2013
  ident: ref_71
  article-title: A cancer-specific variant of the slco1b3 gene encodes a novel human organic anion transporting polypeptide 1b3 (oatp1b3) localized mainly in the cytoplasm of colon and pancreatic cancer cells
  publication-title: Mol. Pharm.
  doi: 10.1021/mp3005353
– volume: 7
  start-page: 1450
  year: 2008
  ident: ref_135
  article-title: Altered expression of organic anion transporter polypeptide (oatp) genes in human breast carcinoma
  publication-title: Cancer Biol. Ther.
  doi: 10.4161/cbt.7.9.6282
– volume: 158
  start-page: 693
  year: 2009
  ident: ref_17
  article-title: Impact of oatp transporters on pharmacokinetics
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2009.00430.x
– volume: 91
  start-page: 14
  year: 2017
  ident: ref_62
  article-title: Contribution of organic anion-transporting polypeptides 1a/1b to doxorubicin uptake and clearance
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.116.105544
– volume: 104
  start-page: 3739
  year: 2004
  ident: ref_101
  article-title: Active transport of imatinib into and out of cells: Implications for drug resistance
  publication-title: Blood
  doi: 10.1182/blood-2003-12-4276
– volume: 66
  start-page: 8847
  year: 2006
  ident: ref_152
  article-title: Organic cation transporters are determinants of oxaliplatin cytotoxicity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-0769
– volume: 50
  start-page: 2289
  year: 2012
  ident: ref_42
  article-title: Ameliorative effects of slc22a2 gene polymorphism 808 g/t and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients
  publication-title: Food Chem. Toxicol.
  doi: 10.1016/j.fct.2012.03.077
– volume: 105
  start-page: 1204
  year: 2019
  ident: ref_117
  article-title: Protein abundance of clinically relevant drug transporters in the human liver and intestine: A comparative analysis in paired tissue specimens
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1301
– volume: 67
  start-page: 44
  year: 2009
  ident: ref_113
  article-title: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2008.03303.x
– ident: ref_231
  doi: 10.3390/children5110145
– volume: 120
  start-page: 2942
  year: 2010
  ident: ref_108
  article-title: Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI42168
– volume: 274
  start-page: 17159
  year: 1999
  ident: ref_10
  article-title: Identification of a novel gene family encoding human liver-specific organic anion transporter lst-1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.24.17159
– volume: 120
  start-page: 181
  year: 2018
  ident: ref_119
  article-title: The scaffold protein pdzk1 modulates expression and function of the organic anion transporting polypeptide 2b1
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2018.05.006
– volume: 338
  start-page: 537
  year: 2011
  ident: ref_175
  article-title: Oxaliplatin transport mediated by organic cation/carnitine transporters octn1 and octn2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.111.181297
– volume: 49
  start-page: 169
  year: 2017
  ident: ref_215
  article-title: Photodynamic diagnosis with 5-aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study
  publication-title: Lasers Surg. Med.
  doi: 10.1002/lsm.22613
– volume: 14
  start-page: 22
  year: 2011
  ident: ref_149
  article-title: Drug transporters of platinum-based anticancer agents and their clinical significance
  publication-title: Drug Resist. Updates
  doi: 10.1016/j.drup.2010.12.002
– volume: 46
  start-page: 592
  year: 2018
  ident: ref_160
  article-title: Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.117.079384
– volume: 48
  start-page: 2094
  year: 1962
  ident: ref_228
  article-title: Basis of actinomycin action. I. DNA binding and inhibition of rna-polymerase synthetic reactions by actinomycin
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.48.12.2094
– volume: 63
  start-page: 77
  year: 2014
  ident: ref_199
  article-title: Pept1- and oat1/3-mediated drug-drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2014.06.019
– volume: 104
  start-page: 139
  year: 2018
  ident: ref_141
  article-title: Influence of oatps on hepatic disposition of erlotinib measured with positron emission tomography
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.888
– volume: 148
  start-page: 75
  year: 2018
  ident: ref_12
  article-title: Lst-3tm12 is a member of the oatp1b family and a functional transporter
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2017.12.012
– volume: 14
  start-page: 275
  year: 1992
  ident: ref_217
  article-title: Endogenous protoporphyrin ix, a clinically useful photosensitizer for photodynamic therapy
  publication-title: J. Photochem. Photobiol. B
  doi: 10.1016/1011-1344(92)85108-7
– volume: 72
  start-page: 729
  year: 2006
  ident: ref_77
  article-title: Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2006.06.007
– volume: 15
  start-page: 4589
  year: 2018
  ident: ref_121
  article-title: Effect of rifampicin on the distribution of [(11)c]erlotinib to the liver, a translational pet study in humans and in mice
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.8b00588
– volume: 68
  start-page: 394
  year: 2018
  ident: ref_2
  article-title: Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 68
  start-page: 94
  year: 2018
  ident: ref_229
  article-title: Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2018.06.013
– volume: 19
  start-page: 1458
  year: 2013
  ident: ref_18
  article-title: Contribution of oatp1b1 and oatp1b3 to the disposition of sorafenib and sorafenib-glucuronide
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-3306
– volume: 21
  start-page: 103
  year: 2011
  ident: ref_68
  article-title: Identification of novel functional organic anion-transporting polypeptide 1b3 polymorphisms and assessment of substrate specificity
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/FPC.0b013e328342f5b1
– volume: 47
  start-page: 1089
  year: 1994
  ident: ref_205
  article-title: Bestatin transport in rabbit intestinal brush-border membrane vesicles
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(94)90421-9
– volume: 93
  start-page: 1
  year: 2018
  ident: ref_180
  article-title: Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating slc22a5 expression
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2018.01.065
– volume: 399
  start-page: 115039
  year: 2020
  ident: ref_67
  article-title: Elucidation of oatp1b1 and 1b3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2020.115039
– volume: 22
  start-page: 1485
  year: 2009
  ident: ref_76
  article-title: Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts
  publication-title: Oncol. Rep.
– volume: 11
  start-page: 584
  year: 2011
  ident: ref_136
  article-title: Expression and localization of the uptake transporters oatp2b1, oatp3a1 and oatp5a1 in non-malignant and malignant breast tissue
  publication-title: Cancer Biol. Ther.
  doi: 10.4161/cbt.11.6.14533
– volume: 107
  start-page: 227
  year: 2020
  ident: ref_26
  article-title: Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1588
– volume: 33
  start-page: 1503
  year: 2005
  ident: ref_99
  article-title: Metabolism and disposition of imatinib mesylate in healthy volunteers
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.105.004283
– volume: 25
  start-page: 2874
  year: 2019
  ident: ref_178
  article-title: L-carnitine-mediated tumor cell protection and poor patient survival associated with octn2 overexpression in glioblastoma multiforme
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2380
– volume: 327
  start-page: 432
  year: 2008
  ident: ref_35
  article-title: Transport of angiotensin-converting enzyme inhibitors by h+/peptide transporters revisited
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.108.143339
– volume: 36
  start-page: 2299
  year: 2008
  ident: ref_164
  article-title: Significance of organic cation transporter 3 (slc22a3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.108.023168
– volume: 95
  start-page: 490
  year: 2019
  ident: ref_66
  article-title: Organic anion transporting polypeptides: Emerging roles in cancer pharmacology
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.118.114314
– volume: 8
  start-page: 567
  year: 2007
  ident: ref_85
  article-title: Novel slc22a16 polymorphisms and influence on doxorubicin pharmacokinetics in asian breast cancer patients
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.8.6.567
– volume: 106
  start-page: 2312
  year: 2017
  ident: ref_90
  article-title: Intestinal drug interactions mediated by oatps: A systematic review of preclinical and clinical findings
  publication-title: J. Pharm. Sci.
  doi: 10.1016/j.xphs.2017.04.004
– volume: 106
  start-page: 297
  year: 2010
  ident: ref_118
  article-title: Human skeletal muscle drug transporters determine local exposure and toxicity of statins
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.109.203596
– volume: 159
  start-page: 898
  year: 2010
  ident: ref_153
  article-title: Differential transport of platinum compounds by the human organic cation transporter hoct2 (hslc22a2)
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2009.00569.x
– volume: 3
  start-page: 37
  year: 2014
  ident: ref_74
  article-title: Unique expression features of cancer-type organic anion transporting polypeptide 1b3 mrna expression in human colon and lung cancers
  publication-title: Clin. Transl. Med.
  doi: 10.1186/s40169-014-0037-y
– volume: 63
  start-page: 157
  year: 2011
  ident: ref_16
  article-title: Organic anion transporting polypeptide 1b1: A genetically polymorphic transporter of major importance for hepatic drug uptake
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.110.002857
– volume: 10
  start-page: 240
  year: 2017
  ident: ref_23
  article-title: Commentary on: “Influence of oatp1b1 function on the disposition of sorafenib-beta-d-glucuronide”
  publication-title: Clin. Transl. Sci.
  doi: 10.1111/cts.12476
– ident: ref_7
– volume: 91
  start-page: 78
  year: 2015
  ident: ref_163
  article-title: Interaction of human organic anion transporter 2 (oat2) and sodium taurocholate cotransporting polypeptide (ntcp) with antineoplastic drugs
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2014.11.002
– volume: 83
  start-page: 1176
  year: 2017
  ident: ref_15
  article-title: Interindividual and interethnic variability in drug disposition: Polymorphisms in organic anion transporting polypeptide 1b1 (oatp1b1; slco1b1)
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/bcp.13207
– volume: 273
  start-page: 20378
  year: 1998
  ident: ref_171
  article-title: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter octn2
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.273.32.20378
– volume: 58
  start-page: 519
  year: 1998
  ident: ref_197
  article-title: An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines aspc-1 and capan-2
  publication-title: Cancer Res.
– volume: 1
  start-page: 1097
  year: 1978
  ident: ref_111
  article-title: Prolongation and enhancement of serum methotrexate concentrations by probenecid
  publication-title: Br. Med. J.
  doi: 10.1136/bmj.1.6120.1097
– volume: 270
  start-page: 25672
  year: 1995
  ident: ref_192
  article-title: Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, pept 1 and pept 2
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.270.43.25672
– volume: 28
  start-page: 4
  year: 2013
  ident: ref_107
  article-title: Impact of genetic variation in oatp transporters to drug disposition and response
  publication-title: Drug Metab. Pharmacokinet.
  doi: 10.2133/dmpk.DMPK-12-RV-099
– ident: ref_183
  doi: 10.1158/1940-6207.CAPR-20-0014
– volume: 440
  start-page: 679
  year: 2000
  ident: ref_191
  article-title: Structural requirements for determining the substrate affinity of peptide transporters pept1 and pept2
  publication-title: Pflugers Arch.
  doi: 10.1007/s004240000339
– volume: 33
  start-page: 265
  year: 2012
  ident: ref_208
  article-title: Organic anion transporters involved in the excretion of bestatin in the kidney
  publication-title: Peptides
  doi: 10.1016/j.peptides.2012.01.007
– volume: 44
  start-page: 1
  year: 2016
  ident: ref_39
  article-title: Organic anion transporting polypeptide (oatp)2b1 contributes to gastrointestinal toxicity of anticancer drug sn-38, active metabolite of irinotecan hydrochloride
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.115.066712
– volume: 342
  start-page: 510
  year: 2012
  ident: ref_81
  article-title: Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.112.192344
– volume: 259
  start-page: 469
  year: 1958
  ident: ref_201
  article-title: Leucine aminopeptidase activity; observations in patients with cancer of the pancreas and other diseases
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM195809042591003
– volume: 8
  start-page: 74348
  year: 2017
  ident: ref_52
  article-title: Upregulated slc22a3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20637
– ident: ref_82
  doi: 10.1371/journal.pone.0064069
– volume: 46
  start-page: 1427
  year: 2016
  ident: ref_214
  article-title: Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ala)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy
  publication-title: Surg. Today
  doi: 10.1007/s00595-016-1328-2
– volume: 19
  start-page: 821
  year: 2013
  ident: ref_59
  article-title: Influence of human oatp1b1, oatp1b3, and oatp1a2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2080
– volume: 139
  start-page: 215
  year: 2019
  ident: ref_221
  article-title: Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter
  publication-title: J. Pharmacol. Sci.
  doi: 10.1016/j.jphs.2019.01.012
– volume: 11
  start-page: 801
  year: 2011
  ident: ref_133
  article-title: The analysis of organic anion transporting polypeptide (oatp) mrna and protein patterns in primary and metastatic liver cancer
  publication-title: Cancer Biol. Ther.
  doi: 10.4161/cbt.11.9.15176
– volume: 99
  start-page: 651
  year: 2016
  ident: ref_51
  article-title: Inherited variation in oatp1b1 is associated with treatment outcome in acute myeloid leukemia
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.315
– volume: 1
  start-page: 661
  year: 2013
  ident: ref_54
  article-title: Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy
  publication-title: Mol. Clin. Oncol.
– volume: 34
  start-page: 95
  year: 2013
  ident: ref_6
  article-title: The abcs of membrane transporters in health and disease (slc series): Introduction
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2012.12.009
– volume: 4
  start-page: 528
  year: 2014
  ident: ref_55
  article-title: High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with folfox-based chemotherapy
  publication-title: Am. J. Cancer Res.
– volume: 5
  start-page: 1
  year: 2013
  ident: ref_70
  article-title: Genetics is a major determinant of expression of the human hepatic uptake transporter oatp1b1, but not of oatp1b3 and oatp2b1
  publication-title: Genome Med.
  doi: 10.1186/gm405
– volume: 110
  start-page: 4064
  year: 2007
  ident: ref_103
  article-title: Most cml patients who have a suboptimal response to imatinib have low oct-1 activity: Higher doses of imatinib may overcome the negative impact of low oct-1 activity
  publication-title: Blood
  doi: 10.1182/blood-2007-06-093617
– volume: 144
  start-page: 1941
  year: 2019
  ident: ref_1
  article-title: Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.31937
– volume: 107
  start-page: 1116
  year: 2020
  ident: ref_95
  article-title: Protein expression and functional relevance of efflux and uptake drug transporters at the blood-brain barrier of human brain and glioblastoma
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1710
– volume: 125
  start-page: 563
  year: 2011
  ident: ref_80
  article-title: Polymorphisms of the nuclear receptor pregnane x receptor and organic anion transporter polypeptides 1a2, 1b1, 1b3, and 2b1 are not associated with breast cancer risk
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-010-1046-1
– volume: 318
  start-page: 521
  year: 2006
  ident: ref_98
  article-title: Interaction of methotrexate with organic-anion transporting polypeptide 1a2 and its genetic variants
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.106.104364
– volume: 101
  start-page: 394
  year: 2012
  ident: ref_151
  article-title: Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.22752
– volume: 368
  start-page: 563
  year: 1994
  ident: ref_188
  article-title: Expression cloning of a mammalian proton-coupled oligopeptide transporter
  publication-title: Nature
  doi: 10.1038/368563a0
– volume: 51
  start-page: 1661
  year: 2017
  ident: ref_182
  article-title: Salicylic acid metabolites and derivatives inhibit cdk activity: Novel insights into aspirin’s chemopreventive effects against colorectal cancer
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2017.4167
– volume: 86
  start-page: 396
  year: 2009
  ident: ref_156
  article-title: Contribution of organic cation transporter 2 (oct2) to cisplatin-induced nephrotoxicity
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2009.139
– volume: 18
  start-page: 726
  year: 2019
  ident: ref_41
  article-title: Germline variant in slco2b1 and response to abiraterone acetate plus prednisone (aa) in new-onset metastatic castration-resistant prostate cancer (mcrpc)
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-18-0739
– volume: 42
  start-page: 1297
  year: 2013
  ident: ref_147
  article-title: Downregulation of organic cation transporter 1 (slc22a1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2013.1840
– volume: 40
  start-page: 649
  year: 1954
  ident: ref_36
  article-title: An unusual and heavy infection of a prawn, pandalus borealis kroyer, by a nematode, Contracaecum sp.
  publication-title: J. Parasitol.
  doi: 10.2307/3273703
– volume: 77
  start-page: 2102
  year: 2017
  ident: ref_53
  article-title: Octn1 is a high-affinity carrier of nucleoside analogues
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-2548
– volume: 419
  start-page: 107
  year: 1997
  ident: ref_170
  article-title: Cloning and characterization of a novel human ph-dependent organic cation transporter, octn1
  publication-title: FEBS Lett.
  doi: 10.1016/S0014-5793(97)01441-5
– volume: 5
  start-page: 497
  year: 2004
  ident: ref_211
  article-title: The present and future role of photodynamic therapy in cancer treatment
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(04)01529-3
– volume: 19
  start-page: 369
  year: 2004
  ident: ref_110
  article-title: Methotrexate-loxoprofen interaction: Involvement of human organic anion transporters hoat1 and hoat3
  publication-title: Drug Metab. Pharmacokinet.
  doi: 10.2133/dmpk.19.369
– ident: ref_159
  doi: 10.3390/genes10050364
– volume: 11
  start-page: 921
  year: 2012
  ident: ref_187
  article-title: Inhibition of octn2-mediated transport of carnitine by etoposide
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0980
– volume: 15
  start-page: 1099
  year: 2013
  ident: ref_48
  article-title: Functional analysis of novel polymorphisms in the human slco1a2 gene that encodes the transporter oatp1a2
  publication-title: AAPS J.
  doi: 10.1208/s12248-013-9515-1
– volume: 15
  start-page: 6062
  year: 2009
  ident: ref_29
  article-title: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and atp-binding cassette transporters
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-0048
– volume: 66
  start-page: 535
  year: 2006
  ident: ref_78
  article-title: Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-a, in human breast carcinoma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-1070
– volume: 75
  start-page: 2729
  year: 2015
  ident: ref_22
  article-title: Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on abcc2, abcc3, and oatp1a/1b
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0280
– volume: 104
  start-page: 682
  year: 2005
  ident: ref_128
  article-title: Phase ii study of tariquidar, a selective p-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.21227
– volume: 2
  start-page: 340
  year: 2016
  ident: ref_127
  article-title: Critical role of pept1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory pept1-mediated tripeptide kpv in a murine model
  publication-title: Cell. Mol. Gastroenterol. Hepatol.
  doi: 10.1016/j.jcmgh.2016.01.006
– volume: 34
  start-page: 352
  year: 2016
  ident: ref_123
  article-title: Association of slco2b1 genotypes with time to progression and overall survival in patients receiving androgen-deprivation therapy for prostate cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.62.5988
– volume: 17
  start-page: 1483
  year: 2016
  ident: ref_25
  article-title: Polymorphisms in slco1b1 and ugt1a1 are associated with sorafenib-induced toxicity
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2016-0063
– volume: 12
  start-page: 1537
  year: 2013
  ident: ref_165
  article-title: Modulation of oatp1b-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-12-0926
– volume: 46
  start-page: 189
  year: 2018
  ident: ref_134
  article-title: Transporter expression in noncancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis c infection quantified by lc-ms/ms proteomics
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.117.077289
– volume: 59
  start-page: 69
  year: 2008
  ident: ref_37
  article-title: Influence of the organic anion-transporting polypeptide 1b1 (oatp1b1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2007.07.019
– ident: ref_220
  doi: 10.1371/journal.pone.0065200
– volume: 90
  start-page: 157
  year: 2011
  ident: ref_45
  article-title: Pharmacokinetic impact of slco1a2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2011.102
– volume: 7
  start-page: 204
  year: 2014
  ident: ref_57
  article-title: Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 3
  start-page: 82
  year: 2011
  ident: ref_32
  article-title: DNA methylation is associated with downregulation of the organic cation transporter oct1 (slc22a1) in human hepatocellular carcinoma
  publication-title: Genome Med.
  doi: 10.1186/gm298
– volume: 95
  start-page: 605
  year: 2003
  ident: ref_210
  article-title: Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage i squamous-cell lung carcinoma
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/95.8.605
– volume: 24
  start-page: 1338
  year: 2017
  ident: ref_125
  article-title: Dual targeting of l-carnitine-conjugated nanoparticles to octn2 and atb(0,+) to deliver chemotherapeutic agents for colon cancer therapy
  publication-title: Drug Deliv.
  doi: 10.1080/10717544.2017.1377316
– volume: 46
  start-page: 793
  year: 2014
  ident: ref_204
  article-title: Positioning of aminopeptidase inhibitors in next generation cancer therapy
  publication-title: Amino Acids
  doi: 10.1007/s00726-013-1648-0
– volume: 94
  start-page: 735
  year: 2016
  ident: ref_3
  article-title: Essential medicines for cancer: Who recommendations and national priorities
  publication-title: Bull. World Health Organ.
  doi: 10.2471/BLT.15.163998
– volume: 4
  start-page: 205
  year: 1992
  ident: ref_209
  article-title: Clinical trials of bestatin for leukemia and solid tumors
  publication-title: Biotherapy
  doi: 10.1007/BF02174207
– volume: 30
  start-page: 2880
  year: 2013
  ident: ref_72
  article-title: Epigenetic regulation of organic anion transporting polypeptide 1b3 in cancer cell lines
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-013-1117-1
– volume: 74
  start-page: 1575
  year: 2018
  ident: ref_227
  article-title: The role of solute carrier (slc) transporters in actinomycin d pharmacokinetics in paediatric cancer patients
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-018-2544-z
– volume: 84
  start-page: 1070
  year: 2012
  ident: ref_86
  article-title: Enhanced expression of organic anion transporting polypeptides (oatps) in androgen receptor-positive prostate cancer cells: Possible role of oatp1a2 in adaptive cell growth under androgen-depleted conditions
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2012.07.026
– volume: 65
  start-page: 11419
  year: 2005
  ident: ref_92
  article-title: Abcc drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-1271
– volume: 72
  start-page: 253
  year: 2020
  ident: ref_143
  article-title: Organic cation transporters in health and disease
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.118.015578
– volume: 51
  start-page: 999
  year: 2019
  ident: ref_194
  article-title: The proton-coupled oligopeptide transporters pept2, pht1 and pht2 mediate the uptake of carnosine in glioblastoma cells
  publication-title: Amino Acids
  doi: 10.1007/s00726-019-02739-w
– volume: 6
  start-page: 16449
  year: 2015
  ident: ref_34
  article-title: Slc15a2 genomic variation is associated with the extraordinary response of sorafenib treatment: Whole-genome analysis in patients with hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3758
– ident: ref_148
  doi: 10.1186/1471-2407-12-109
– volume: 113
  start-page: 1114
  year: 2006
  ident: ref_168
  article-title: Uptake of cardiovascular drugs into the human heart: Expression, regulation, and function of the carnitine transporter octn2 (slc22a5)
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.105.586107
– volume: 94
  start-page: 585
  year: 2013
  ident: ref_158
  article-title: Conjunctive therapy of cisplatin with the oct2 inhibitor cimetidine: Influence on antitumor efficacy and systemic clearance
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2013.145
– volume: 97
  start-page: 907
  year: 2012
  ident: ref_104
  article-title: Chronic phase chronic myeloid leukemia patients with low oct-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.056457
– volume: 73
  start-page: 606
  year: 2012
  ident: ref_65
  article-title: Influence of slco1b3 haplotype-tag snps on docetaxel disposition in Chinese nasopharyngeal cancer patients
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2011.04123.x
– volume: 20
  start-page: 985
  year: 2014
  ident: ref_102
  article-title: Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (oct1)
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1999
– volume: 294
  start-page: 73
  year: 2000
  ident: ref_91
  article-title: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 10
  start-page: 477
  year: 2013
  ident: ref_195
  article-title: Expression profile and functional activity of peptide transporters in prostate cancer cells
  publication-title: Mol. Pharm.
  doi: 10.1021/mp300364k
– volume: 74
  start-page: 477
  year: 2007
  ident: ref_155
  article-title: Differential contribution of organic cation transporters, oct2 and mate1, in platinum agent-induced nephrotoxicity
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2007.03.004
– volume: 128
  start-page: 1373
  year: 1993
  ident: ref_83
  article-title: Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine i 123 at 16 alpha
  publication-title: Arch. Surg.
  doi: 10.1001/archsurg.1993.01420240081016
– volume: 60
  start-page: 19
  year: 2007
  ident: ref_185
  article-title: Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-006-0341-3
– volume: 10
  start-page: 412
  year: 2017
  ident: ref_161
  article-title: Identification of oat1/oat3 as contributors to cisplatin toxicity
  publication-title: Clin. Transl. Sci.
  doi: 10.1111/cts.12480
– volume: 196
  start-page: 204
  year: 2019
  ident: ref_138
  article-title: Organic anion transporting polypeptide 2b1—More than a glass-full of drug interactions
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2018.12.009
– volume: 35
  start-page: 1473
  year: 2008
  ident: ref_84
  article-title: [18f]fluorinated estradiol derivatives for oestrogen receptor imaging: Impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-008-0745-x
– volume: 136
  start-page: 225
  year: 2015
  ident: ref_60
  article-title: Human oatp1b1, oatp1b3 and oatp1a2 can mediate the in vivo uptake and clearance of docetaxel
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.28970
– volume: 106
  start-page: 228
  year: 2019
  ident: ref_94
  article-title: Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1373
– volume: 18
  start-page: 4433
  year: 2012
  ident: ref_64
  article-title: Influence of polymorphic oatp1b-type carriers on the disposition of docetaxel
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-0761
– volume: 176
  start-page: 787
  year: 2019
  ident: ref_33
  article-title: Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.14563
– volume: 15
  start-page: 179
  year: 2017
  ident: ref_213
  article-title: Intraoperative 5-aminolevulinic acid-induced photodynamic diagnosis of metastatic brain tumors with histopathological analysis
  publication-title: World J. Surg. Oncol.
  doi: 10.1186/s12957-017-1239-8
– volume: 26
  start-page: 234
  year: 1992
  ident: ref_112
  article-title: Methotrexate and nonsteroidal antiinflammatory drug interactions
  publication-title: Ann. Pharmacother.
  doi: 10.1177/106002809202600219
– volume: 5
  start-page: 1122
  year: 2008
  ident: ref_225
  article-title: Targeted disruption of peptide transporter pept1 gene in mice significantly reduces dipeptide absorption in intestine
  publication-title: Mol. Pharm.
  doi: 10.1021/mp8001655
– volume: 18
  start-page: 49
  year: 2018
  ident: ref_49
  article-title: Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib
  publication-title: Pharmacogenet. J.
  doi: 10.1038/tpj.2016.83
– volume: 20
  start-page: 619
  year: 2011
  ident: ref_87
  article-title: Expression of slco transport genes in castration-resistant prostate cancer and impact of genetic variation in slco1b3 and slco2b1 on prostate cancer outcomes
  publication-title: Cancer Epidemiol. Biomark. Prev.
  doi: 10.1158/1055-9965.EPI-10-1023
– volume: 46
  start-page: 779
  year: 2018
  ident: ref_174
  article-title: Substrate selectivity check of the ergothioneine transporter
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.118.080440
– volume: 273
  start-page: 5582
  year: 1998
  ident: ref_207
  article-title: Interaction of beta-lactam antibiotics with histidine residue of rat h+/peptide cotransporters, pept1 and pept2
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.273.10.5582
– volume: 56
  start-page: 287
  year: 2017
  ident: ref_106
  article-title: Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients
  publication-title: Clin. Pharmacokinet.
  doi: 10.1007/s40262-016-0439-7
– volume: 68
  start-page: 9338
  year: 2008
  ident: ref_79
  article-title: Interplay between the nuclear receptor pregnane x receptor and the uptake transporter organic anion transporter polypeptide 1a2 selectively enhances estrogen effects in breast cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-0265
– volume: 47
  start-page: 832
  year: 2019
  ident: ref_140
  article-title: Fexofenadine and rosuvastatin pharmacokinetics in mice with targeted disruption of organic anion transporting polypeptide 2b1
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.119.087619
– volume: 85
  start-page: 155
  year: 2009
  ident: ref_63
  article-title: Pharmacogenetic pathway analysis of docetaxel elimination
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2008.95
– volume: 8
  start-page: 40454
  year: 2017
  ident: ref_198
  article-title: Targeting pept1: A novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17117
– volume: 122
  start-page: 519
  year: 2012
  ident: ref_21
  article-title: Complete oatp1b1 and oatp1b3 deficiency causes human rotor syndrome by interrupting conjugated bilirubin reuptake into the liver
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI59526
– volume: 153
  start-page: 383
  year: 2015
  ident: ref_50
  article-title: High-throughput pharmacogenetics identifies slco1a2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer rapp-01 trial
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-015-3552-7
– volume: 45
  start-page: 1763
  year: 1993
  ident: ref_206
  article-title: Transport of bestatin in rat renal brush-border membrane vesicles
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/0006-2952(93)90431-U
– volume: 273
  start-page: 251
  year: 2000
  ident: ref_89
  article-title: Molecular identification and characterization of novel members of the human organic anion transporter (oatp) family
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.2000.2922
– volume: 1235
  start-page: 461
  year: 1995
  ident: ref_189
  article-title: Molecular cloning of pept 2, a new member of the h+/peptide cotransporter family, from human kidney
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/0005-2736(95)80036-F
– volume: 30
  start-page: 507
  year: 2020
  ident: ref_4
  article-title: The future of cancer immunotherapy: Microenvironment-targeting combinations
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0337-2
– volume: 33
  start-page: 3036
  year: 2015
  ident: ref_230
  article-title: Ewing sarcoma: Current management and future approaches through collaboration
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.59.5256
– ident: ref_56
  doi: 10.1371/journal.pone.0148739
– volume: 10
  start-page: 271
  year: 2017
  ident: ref_24
  article-title: Influence of oatp1b1 function on the disposition of sorafenib-beta-d-glucuronide
  publication-title: Clin. Transl. Sci.
  doi: 10.1111/cts.12458
– volume: 13
  start-page: 866
  year: 2002
  ident: ref_146
  article-title: Gene expression levels and immunolocalization of organic ion transporters in the human kidney
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.V134866
– volume: 83
  start-page: 1218
  year: 2013
  ident: ref_137
  article-title: Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2b1 transcriptional start site variant
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.112.083618
– volume: 27
  start-page: 72
  year: 2016
  ident: ref_20
  article-title: The impact of organic anion-transporting polypeptides (oatps) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice
  publication-title: Drug Resist. Updates
  doi: 10.1016/j.drup.2016.06.005
– ident: ref_131
  doi: 10.1186/s12885-017-3728-0
– volume: 14
  start-page: 994
  year: 2015
  ident: ref_61
  article-title: Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-14-0547
– volume: 6
  start-page: 929
  year: 2010
  ident: ref_212
  article-title: Future of oncologic photodynamic therapy
  publication-title: Future Oncol.
  doi: 10.2217/fon.10.51
– ident: ref_30
  doi: 10.1186/s12885-016-2150-3
– volume: 120
  start-page: 1689
  year: 2001
  ident: ref_11
  article-title: Lst-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers
  publication-title: Gastroenterology
  doi: 10.1053/gast.2001.24804
– volume: 17
  start-page: 1987
  year: 2020
  ident: ref_93
  article-title: Oatp1a2 and oatp2b1 are interacting with dopamine-receptor agonists and antagonists
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.0c00159
– volume: 13
  start-page: 492
  year: 2014
  ident: ref_19
  article-title: Oatp1a/1b transporters affect irinotecan and sn-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-13-0541
– volume: 98
  start-page: 193
  year: 2013
  ident: ref_44
  article-title: Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
  publication-title: Haematologica
  doi: 10.3324/haematol.2012.066480
– volume: 29
  start-page: 1960
  year: 2015
  ident: ref_105
  article-title: Oct1 and imatinib transport in cml: Is it clinically relevant?
  publication-title: Leukemia
  doi: 10.1038/leu.2015.170
– volume: 418
  start-page: 818
  year: 2012
  ident: ref_73
  article-title: Identification of a new organic anion transporting polypeptide 1b3 mrna isoform primarily expressed in human cancerous tissues and cells
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2012.01.115
– volume: 230
  start-page: 72
  year: 2005
  ident: ref_196
  article-title: Regulation of human peptide transporter 1 (pept1) in gastric cancer cells by anticancer drugs
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2004.12.023
– volume: 38
  start-page: 501
  year: 2017
  ident: ref_114
  article-title: Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3
  publication-title: Biopharm. Drug Dispos.
  doi: 10.1002/bdd.2091
– volume: 447
  start-page: 653
  year: 2004
  ident: ref_9
  article-title: Organic anion transporting polypeptides of the oatp/slc21 family: Phylogenetic classification as oatp/slco superfamily, new nomenclature and molecular/functional properties
  publication-title: Pflugers Arch.
  doi: 10.1007/s00424-003-1168-y
– volume: 48
  start-page: 419
  year: 2020
  ident: ref_139
  article-title: Role of oatp2b1 in drug absorption and drug-drug interactions
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.119.090316
– ident: ref_224
  doi: 10.3390/molecules25030643
– volume: 95
  start-page: 201
  year: 2015
  ident: ref_75
  article-title: Genetic polymorphisms and function of the organic anion-transporting polypeptide 1a2 and its clinical relevance in drug disposition
  publication-title: Pharmacology
  doi: 10.1159/000381313
– volume: 36
  start-page: 963
  year: 2006
  ident: ref_116
  article-title: Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition
  publication-title: Xenobiotica
  doi: 10.1080/00498250600861751
– volume: 58
  start-page: 1065
  year: 2013
  ident: ref_28
  article-title: Expression of slc22a1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
  publication-title: Hepatology
  doi: 10.1002/hep.26425
– volume: 81
  start-page: 362
  year: 2007
  ident: ref_169
  article-title: Intestinal drug transporter expression and the impact of grapefruit juice in humans
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/sj.clpt.6100056
– volume: 14
  start-page: 3141
  year: 2008
  ident: ref_96
  article-title: Interaction of imatinib with human organic ion carriers
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-4913
– volume: 23
  start-page: 4592
  year: 2017
  ident: ref_40
  article-title: Association of tissue abiraterone levels and slco genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2245
– volume: 109
  start-page: 1274
  year: 1995
  ident: ref_88
  article-title: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(95)90588-X
– volume: 34
  start-page: 397
  year: 1994
  ident: ref_97
  article-title: The methotrexate story: A paradigm for development of cancer chemotherapeutic agents
  publication-title: Adv. Enzyme Regul.
  doi: 10.1016/0065-2571(94)90025-6
– volume: 55
  start-page: 60
  year: 2017
  ident: ref_130
  article-title: The selective tyrosine kinase-inhibitor nilotinib alleviates experimentally induced cisplatin nephrotoxicity and heptotoxicity
  publication-title: Environ. Toxicol. Pharmacol.
  doi: 10.1016/j.etap.2017.08.008
– volume: 72
  start-page: 25
  year: 2015
  ident: ref_120
  article-title: Expression of oatp2b1 as determinant of drug effects in the microcompartment of the coronary artery
  publication-title: Vasc. Pharmacol.
  doi: 10.1016/j.vph.2015.06.006
– volume: 33
  start-page: 1867
  year: 2010
  ident: ref_157
  article-title: Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity
  publication-title: Biol. Pharm. Bull.
  doi: 10.1248/bpb.33.1867
– volume: 61
  start-page: 853
  year: 2002
  ident: ref_166
  article-title: Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(ii) and cis-diammine-bisursodeoxycholate-platinum(ii) toward liver cells
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.61.4.853
– volume: 16
  start-page: 821
  year: 2018
  ident: ref_216
  article-title: Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy
  publication-title: Oncol. Lett.
SSID ssj0000331767
Score 2.3520494
SecondaryResourceType review_article
Snippet Solute carrier transporters comprise a large family of uptake transporters involved in the transmembrane transport of a wide array of endogenous substrates...
SourceID pubmedcentral
proquest
gale
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 2263
SubjectTerms ABC transporters
Cancer
Cancer therapies
Care and treatment
Carnitine
Cell division
Chemotherapy
DNA topoisomerase inhibitors
Drug metabolism
Drug therapy
Drugs
Etiology
Genes
Hormones
Kinases
Liver cancer
Metabolism
Metabolites
Nutrients
Observations
Organic anion transporting polypeptide
Pharmaceuticals
Pharmacokinetics
Polypeptides
Protein-tyrosine kinase
Proteins
Review
Studies
Thrombocytopenia
Toxicity
Tumor cells
Tumors
Title Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?
URI https://www.proquest.com/docview/2434585362
https://www.proquest.com/docview/2435186326
https://pubmed.ncbi.nlm.nih.gov/PMC7464370
Volume 12
WOSCitedRecordID wos000578905300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M~E
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M7P
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Research Library
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M2O
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Pb9MwFLfYhhCX8XeiY0xG4sBhYYkdx8lpClUnkGiJoEjlFDm2I6pVSUk6ztz4AnxCPgnvJW5HK8GFSxLHf2Ln2c-_Z1u_R8iLxBimAEZ7Jcw-XqjL0CsAWHhWSAv6sORKlJ2zCTmZxLNZkrkFt9Ydq1zrxE5Rm1rjGvk5C3kI0Bb07cXyq4deo3B31bnQ2CMHyFQG_fzg9WiSfdissvgc5sdI9pw-HOz7c40_s2kDhlTnEd-ajnaV8u5ByT9mnst7_1vn--TQYU6a9p3kAbllq4fkztjtqj8iPz4tV-rK0hui86aldUkBG9KP74YsOOtuLD2jqjL4HIiUdi4zwM6m84qmFS6JY5PptKcp-PX957g26Bus7gsb2sUCj7zSEboyoXVDM8eafQWVQLLoi8dkejmaDt94zkGDp8OErTwhDC94IUqpitj6FsCn4oYzK0BzWDAEI8ZiHSlmotg3EFQAvnQc2yQ0AHT4Edmv6so-ITQCHBELZNeDOGX9wpTQgZThgdaxLOWAvFqLKdeOvBx9aCxyMGJQrvmOXAfk5SbDsuft-HvSE5R7jiMaytQwvnSeInKLEhEGEL0Wbu7Gd5vfSHZAnm-iMSeeWatsfd2lEdAgwMcDIrf60aZGyO29HVPNv3Qc3zLEHVX_-N8ff0ruMrT_kaKXnZD9VXNtn5Hb-ttq3janZE_O4lM3JCA0Zu_xKjN4l70dZ59_A5sbGpc
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL2qUgRseCNSCgwSSCzq1p7xc4GqKLRq1CSKRJDKyhrPjEXUyE7tFMSOHT_Ab_BTfAn3-pGSSLDrglUcje044zP3nhlfnwPwKtKaS6TRVorZx3JV6loJEgvLeIHBeJgK6aWV2UQwHodnZ9FkC36278JQWWUbE6tArXNFa-QH3BUuUluMt4eLC4tco-jpamuhUcPi1Hz9glO28u3gHd7f15wfH037J1bjKmApN-JLy_O0SETipYFMQmMbZExSaMGNh3A3OHvxOQ-VL7n2Q1vjV4mMQYWhiVztVyYRGPG3XcS63YHtyWA0-bha1LEFpmM_qCWEhIjsA0X3rigdTsrqvljLfps5YLMu849Ed3z3P-uie3CnYdSsVw-B-7Blsgdwc9TUDDyE7x8WS3lu2JWMe1GyPGXIfNn7YZ87e9UH7-0xmWnadrweqwxBZqZks4z1Mlrwpx5m01qE4de3H6Nck_NZXp-sb-ZzKuhlR2TUwvKCTRpN8HO8CJLCPnwE0-vohcfQyfLMPAHmI0sKPdIOxDZp7ESnODykFo5SYZAGXdhvURGrRpqdHELmMU7RCEbxBoy68GZ1wKJWJfn7rrsEs5jiFZ5TYfRQcY94qR95roPNLZbiJnqV8RWQuvBy1UxHUkVeZvLLah8P_xCy_y4Ea7BdXREpl6-3ZLNPlYJ54NLzYnvn3z_-Am6dTEfDeDgYnz6F25xWOkiMmO9CZ1lcmmdwQ31ezsrieTMOGcTXDOvfGBtwCw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL2qUlSx4Y0ILTBIILGoiT3j8WOBqpAmomobRRCk7ix7ZiyiRnZqpyB27PgBfobf4Uu414-URIJdF6xsa8av8Zl7z8xcnwvwItSax0ijrRS9j-Wq1LUSJBaWkb5Be5iKWKZVsgl_PA7OzsLJFvxs_4WhsMrWJlaGWueK5sh73BUuUlu0t720CYuYHI4OFhcWZZCildY2nUYNkWPz9QsO38o3R4f4rV9yPhpOB--sJsOApdyQLy0ptUhEIlM_TgJjG2RPsdCCG4nQNziS8TgPlBdz7QW2xsMY2YMKAhO62qsSRqD13_YF1uzA9tvhePJ-NcFjC3TNnl_LCQkR2j1F37EoHU4q655Y84Sb_mAzRvMPpze6_R831x241TBt1q-7xl3YMtk92DltYgnuw_ePi2V8btiVvHtRsjxlyIjZh5MBd_arDe_vszjTtO_IPqsShcxMyWYZ62e0EECtzaa1OMOvbz9Oc00Z0fL6YgMzn1OgLxtSAheWF2zSaIWf40OQRPbBA5heRys8hE6WZ-YRMA_ZUyBJUxDLYmMnOsVuE2vhKBX4qd-F1y1CItVItlPmkHmEQzeCVLQBqS68Wp2wqNVK_l51jyAXkR3Dayq0KirqE1_1Quk6WNziKmqsWhldgaoLz1fFdCZF6mUmv6zqSHwhHBV0wV-D8OqJSNF8vSSbfaqUzX2X1pHtx_---TPYQSxHJ0fj4124yWkChDSK-R50lsWleQI31OflrCyeNl2SQXTNqP4N2e54pQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uptake+Transporters+of+the+SLC21%2C+SLC22A%2C+and+SLC15A+Families+in+Anticancer+Therapy%E2%80%93Modulators+of+Cellular+Entry+or+Pharmacokinetics%3F&rft.jtitle=Cancers&rft.au=Brecht%2C+Karin&rft.au=Schafer%2C+Anima+Magdalena&rft.au=Schwabedissen%2C+Henriette+E.+Meyer+zu&rft.date=2020-08-12&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=12&rft.issue=8&rft.spage=1&rft_id=info:doi/10.3390%2Fcancers12082263&rft.externalDocID=A639969541
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon